Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CymaBay Therapeutics
Biotech
Gilead pays J&J $320M to exit licensing deal for seladelpar
With Gilead on the verge of an FDA decision for seladelpar, it has paid J&J $320M to exit an 18-year-old licensing agreement on the drug.
Kevin Dunleavy
Aug 9, 2024 10:30am
Gilead shows $4.3B liver drug improves outcomes out to 2 years
Jun 5, 2024 7:33am
Gilead liver disease med still delivers ahead of FDA verdict
May 20, 2024 8:30am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
Gilead pays $4.3B for CymaBay's late-stage liver disease med
Feb 12, 2024 9:01am
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
Nov 14, 2023 5:55am
